



AstraZeneca Pharma India Limited

Regd. Office: 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2011

Rs in lakhs (except for number of shares)

Sl No.	Particulars	3 months ended	3 months ended	3 months ended	Year to date	Year to date	Previous
		31.12.2011	30.09.2011	31.12.2010	figure for 9 months ended 31.12.2011	figure for 12 months ended 31.12.2010	accounting year (15 months period) ended 31.03.2011
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	(a) Net sales (net of excise duty)	14,516.55	14,201.37	12,845.04	41,659.74	45,105.73	57,436.20
	(b) Other operating income:						
	- Service income	831.78	661.06	407.25	2,299.25	1,629.09	1,966.30
2	Expenditure						
	(a) (Increase) / decrease in stock-in-trade and work-in-progress	(1,941.87)	(93.05)	(838.16)	(3,426.54)	(1,259.17)	(1,358.95)
	(b) Consumption of raw materials and packing materials	1,349.33	1,993.81	1,602.63	5,742.23	5,963.96	7,604.40
	(c) Purchase of traded goods	5,320.28	2,620.13	3,175.12	11,088.85	9,262.29	11,681.17
	(d) Employees cost	3,523.09	3,523.44	2,542.19	10,400.15	11,220.15	15,049.76
	(e) Depreciation	188.81	191.28	185.37	552.83	705.65	881.28
	(f) Other expenditure	4,859.03	3,639.80	2,458.99	12,226.29	12,855.72	16,074.49
	(g) Total	13,298.67	11,875.41	9,126.14	36,583.81	38,748.60	49,932.15
3	Profit from operations before other income, interest & exceptional items (1-2)	2,049.66	2,987.02	4,126.15	7,375.18	7,986.22	9,470.35
4	Other income	150.32	145.39	153.32	445.98	408.35	628.14
5	Profit before interest & exceptional items (3+4)	2,199.98	3,132.41	4,279.47	7,821.16	8,394.57	10,098.49
6	Interest	-	-	-	-	-	-
7	Profit after interest but before exceptional items (5-6)	2,199.98	3,132.41	4,279.47	7,821.16	8,394.57	10,098.49
8	Exceptional items	-	-	-	-	-	-
9	Profit from ordinary activities before tax (7+8)	2,199.98	3,132.41	4,279.47	7,821.16	8,394.57	10,098.49
10	Tax expense	706.24	1,024.01	1,447.31	2,544.20	2,816.99	3,685.52
11	Net profit from ordinary activities after tax (9-10)	1,493.74	2,108.40	2,832.16	5,276.96	5,577.58	6,412.97
12	Extraordinary item	-	-	-	-	-	-
13	Net profit for the period (11-12)	1,493.74	2,108.40	2,832.16	5,276.96	5,577.58	6,412.97
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year	-	-	-	-	-	17,468.96
16	Basic and diluted earnings (Rs) per share (not annualised)	5.97	8.43	11.33	21.11	22.31	25.65
17	Public shareholding						
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
18	Promoters and promoter group shareholding						
	a) Pledged/Encumbered						
	- Number of shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 2 February 2012.
- Status of investor complaints: a) Pending as on 1 October 2011 - NIL b) Received during the quarter - 1 c) Disposed off during the quarter - 1 d) Pending as on 31 December 2011 - NIL.
- The Board of Directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April- March". The financial accounts and annual report for the year ended 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current period ended 31 December 2011 are for a 9 months period, while the corresponding figures are for a 12 months period and hence not strictly comparable.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
- The above statement of financial results have been subjected to limited review by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filed with the stock exchange and is also available on the Company's website.

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

Rs in lakhs

Sl No.	Particulars	3 months ended	3 months ended	3 months ended	Year to date	12 months ended	Previous
		31.12.2011	30.09.2011	31.12.2010	figure for 9 months ended 31.12.2011	31.12.2010	accounting year (15 months period) ended 31.03.2011
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment revenue						
	(a) Healthcare	14,520.44	14,205.80	12,850.94	41,674.10	45,128.21	57,464.43
	(b) Others	831.78	661.06	407.25	2,299.25	1,629.09	1,966.30
	Total	15,352.22	14,866.86	13,258.19	43,973.35	46,757.30	59,430.73
	Less: Inter-segment Revenue						
	Net income from operations	15,352.22	14,866.86	13,258.19	43,973.35	46,757.30	59,430.73
2	Segment results						
	Profit before tax and interest						
	(a) Healthcare	2,047.28	2,923.52	4,077.58	7,287.85	7,847.06	9,386.50
	(b) Others	6.27	67.93	54.47	101.68	161.64	112.08
	Total	2,053.55	2,991.45	4,132.05	7,389.53	8,008.70	9,498.58
	Add: Other income	146.43	140.96	147.42	431.63	385.87	599.91
	Less: Interest						
	Total profit before tax	2,199.98	3,132.41	4,279.47	7,821.16	8,394.57	10,098.49
3	Capital employed						
	(a) Healthcare	15,527.13	14,973.36	10,499.73	15,527.13	10,499.73	12,122.33
	(b) Others	562.23	463.97	24.65	562.23	24.65	644.20
	(c) Unallocated	7,156.55	6,314.85	9,514.67	7,156.55	9,514.67	5,202.43
	Total	23,245.91	21,752.18	20,039.05	23,245.91	20,039.05	17,968.96

Notes:

- 1 Note: Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- 2 The Board of Directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April- March". The financial accounts and annual report for the year ended 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current period ended 31 December 2011 are for a 9 months period, while the corresponding figures are for a 12 months period and hence not strictly comparable.

**By Order of the Board of Directors
For AstraZeneca Pharma India Limited**

Anandh Balasundaram
Managing Director

Place : Bangalore
Dated : 2 February 2012